• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Switzerland·Healthcare·ALC.SW
Held by 2 Gurus
Share

Alcon Inc. Stocks

CHF 58.46Last Updated 27.08.2026

Issuer Rating

6/7
Performance

Favourable

Risk

Low

Recommendation

Buy

Market Cap

CHF 35.78B

CHF 58.46
Key Takeaways

Risk factor

Negligible price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Good growth

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

In Guru Portfolios

Kenneth Griffin

Portfolio Weight (%)

0.0%

Change

+0.00%

Fund

CITADEL ADVISORS LLC

Steven Cohen

Portfolio Weight (%)

0.0%

Change

-0.11%

Fund

Point72 Asset Management, L.P.

Manager
Fund
Portfolio Weight (%)
Change
Kenneth GriffinCITADEL ADVISORS LLC0.0%+0.00%
Steven CohenPoint72 Asset Management, L.P.0.0%-0.11%

Latest news

13.08.2026 13:56

Netflix and 5 Other New Stocks: Ekman's Fund Sharply Increased Its Purchases in the Second Quarter

27.01.2026 18:10

UBS shares top European picks ahead of earnings season, incl. three small caps

06.08.2025 15:19

Shares of implantable lens maker STAAR jump 46% as company to be acquired by Alcon

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Alcon Inc. is a global eye care enterprise dedicated to the research, development, manufacturing, and distribution of a comprehensive range of vision products for both eye care professionals and their patients worldwide. The company operates through two primary divisions. Its Surgical segment equips ophthalmic surgeons with advanced solutions for various procedures. This includes specialized equipment, diagnostic instrumentation, and implantable devices such as intraocular lenses (IOLs), alongside a full suite of consumables like viscoelastic substances, surgical solutions, and customized procedure kits. For cataract interventions, key offerings feature the Centurion Vision System, LenSx femtosecond laser, LuxOR surgical ophthalmic microscope, NGENUITY 3D visualization system, and ORA System for intra-operative measurements. Vitreoretinal surgeons benefit from systems like Constellation Vision, procedure packs, lasers, and a variety of specialized micro-instruments, including grieshaber and MIVS tools, scissors, forceps, medical-grade vitreous tamponades, and Hypervit vitrectomy probes. Refractive surgery innovations include WaveLight lasers and Contoura Vision for LASIK treatments, and the segment also provides the EX-PRESS glaucoma filtration device. Its IOL portfolio, prominently featuring AcrySof IQ, includes advanced technology lenses like PanOptix and ReSTOR, designed to correct presbyopia and astigmatism during cataract removal. The Vision Care segment addresses everyday eye health needs. It offers a diverse selection of contact lenses, including daily disposables, reusable options, and color-enhancing varieties. This segment also provides ocular health products for conditions such as dry eye, glaucoma, and allergies, in addition to contact lens care solutions, ocular vitamins, and redness-relieving drops. Prominent brands within this segment include TOTAL, PRECISION, DAILIES AquaComfort PLUS, Air Optix, Opti-Free, Clear Care, Tears Naturale, Genteal, ICAPS, and Vitalux. Founded in 1945, the company was initially known as Alcon Universal S.A. before rebranding as Alcon Inc. in December 2001. Its headquarters are located in Geneva, Switzerland.

Company Valuation

Fairly valued
4/7

Based on key historical and expected multiples, the stock is fairly valued relative to its peers. In particular, the stock is reasonably priced on P/E, of fair value on E

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Somewhat favourable
5/7

The average target price of ALC.SW is 70.4 and suggests 20.4% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to in

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

28.08.2026 23:34

"Worsha was seen as a hawk": The market sharply raised expectations for a rate hike in September

28.08.2026 21:40

"The Schrodinger's Cat Situation": Analysts Take Stock of Six Months of the U.S.-Iran War

28.08.2026 20:58

BioNTech and Roche have halted a cancer vaccine trial. What does this mean for the industry?

28.08.2026 19:14

The Fed "has a lot of work ahead" if inflation doesn't come down quickly — Warsh

28.08.2026 19:05

"The Main Focus for the Markets": What to Expect from the Fed Chair's Speech in Jackson Hole

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026